Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy

Clinica Chimica Acta

Volumn 292, Issue 1-2, 2000, Pages 127-138

  Scorilas, Andreas ^a,d   Yu, He ^b   Soosaipillai, Antoninus R ^d   Gregorakis, Alkiviades K ^c   Diamandis, Eleftherios P ^a,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c EVANGELISMOS HOSPITAL   (Greece)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Free prostate specific antigen; Prostate cancer relapse; Prostate specific antigen; Tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECURRENT CANCER;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0033976540     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00211-9     Document Type: Article

References (28)

1. Diamandis E.P. Prostate specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab. 9:1998;310-316.
2. Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen:Update 1994. J Urol. 152:1994;1358-1368.
3. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol. 152:1994;2032-2037.
4. Catalona W.J., Richie J.P., Ahmann F.K., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 151:1994;1283-1290.
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
6. 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
7. Magklara A., Scorilas A., Catalona W.J., Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 45:1999;1960-1966.
8. Luderer A.A., Chen Y., Soriano T.F., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 46:1995;187-194.
9. Catalona W.J. Clinical utility of measurement of free and total prostate specific antigen (PSA): A Review. The Prostate. 7:1996;64-69.
10. Partin A.W., Carter H.B. The use of prostate-specific antigen and free/total prostate- specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Amer. 23:1996;531-540.
11. Woodrum D.L., Brawer M.K., Partin A.W. Catalona WJ,et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer: A review. J Urol. 159:1998;5-12.
12. Partin A.W., Catalona W.J., Southwick P.C., et al. Analysis of percent free prostate- specific antigen PSA for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 48:1996;55-61.
13. Ornstein D.K., Smith D.S., Humphrey P.A., Catalona W.J. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol. 159:1996;1234-1237.
14. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed, and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 154:1995;1090-1095.
15. Arcangeli C.G., Shepherd D.L., Smith D.S., et al. Correlation of percent free PSA with pathologic features of prostatic carcinomas (abstract). J Urol. 155:1996;415A.
16. Elgamal A.A., Cornillie F.J., van Poppel H.P., et al. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol. 156:1996;1047-1049.
17. Pannek J., Subong E.N.P., Jones K., et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology. 48:1996;51-54.
18. Graefen M, Hammerer P, Henke P, et al. Percentage of free PSA does not correlate with pathological outcome (abstract 237). J Urol 1996;155:370A.
19. Henricks W.H., England B.G., Giacherio D.A. et al. Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma (abstract 236). J Urol. 155:1996;369A.
20. Bangma C.H., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol. 157:1997;544-547.
21. Pannek J., Rittenhouse H.G., Chan D.W., et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol. 159:1998;1238-1242.
22. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. J Am Med Assoc. 279:1998;1542-1547.
23. Lin D.W., Noteboom J.L., Blumenstein B.A., Ellis W.J., Lange P.H., Vessella R.L. Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology. 52:1998;366-371.
24. Wojno K.J., Vashi A.R., Schellhammer P.F., Wright G.L. Jr., Monte J.E. Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy. Urology. 52:1998;474-478.
25. Yu H., Diamandis E.P., Wong P-Y., Nam R., Trachtenberg J. Detection of prostate relapse with prostate specific antigen monitoring at levels between 0.001 and 01 ug/l. J Urol. 157:1997;913-918.
26. Diamandis E.P., Yu H., Melegos D.N. Ultrasensitive prostate specific antigen assays and their clinical application. Clin Chem. 42:1996;853-857.
27. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the reflex range and appropriate cutpoints for percent free PSA in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 49:1997;19-27.
28. Lerner S.E., Jacobsen S.J., Lilja H., et al. Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology. 42:1996;240-248.